Timeliness of antiviral therapy for newly reported HIV/AIDS cases in Yichang City in 2016－2022
10.3969/j.issn.1006-2483.2024.05.028
- VernacularTitle:2016—2022年宜昌市新报告HIV/AIDS病例抗病毒治疗及时性分析
- Author:
Jie MIN
1
;
Dingyuan ZHAO
2
;
Hao ZHANG
1
;
Wen LEI
1
;
Yu TIAN
1
;
Fangfang LI
1
Author Information
1. Yichang Municipal Center for Disease Control and Prevention ,Yichang , Hubei 443000 , China
2. Hubei Provincial Center for Disease Control and Prevention ,Wuhan , Hubei 430079 , China
- Publication Type:Journal Article
- Keywords:
HIV/AIDS;
Antiretroviral therapy;
Timeliness
- From:
Journal of Public Health and Preventive Medicine
2024;35(5):117-120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the timeliness of antiretroviral therapy (ART) in newly reported HIV/AIDS cases in Yichang from 2016 to 2022 and its influencing factors, and to provide a scientific basis for improving the timeliness of ART in Yichang City. Methods HIV/AIDS cases data from January 1, 2016 to December 31, 2022 were collected, and chi-square tests and logistic regression were used to analyze the factors influencing the timeliness of ART. Results A total of 1 126 HIV/AIDS cases were collected, with local reported cases accounting for 83.13%. The male to female ratio was 5.15:1. The median age was 42 years old (28-53 years old). 41.03% of the cases were unmarried. 38.99% of cases had a first-time CD4+T lymphocytes (CD4 cells) count < 200 cells/µL. Cases with timely first CD4 cell test accounted for 67.85%. The overall timely rate of ART from 2016 to 2022 was 57.19%, with a median time from diagnosis to initiation of ART of 20 days. There was no statistically significant difference in the trend of ART timely rate from 2016 to 2022 (P=0.251). Cases with timely first CD4 cell test were more likely to initiate ART in time (OR=3.831, 95% CI:2.454-5.981), while cases reported from other areas (OR=0.497, 95% CI:0.345-0.716) and cases with higher first CD4 cell count levels (OR≥500=0.473, 95% CI:0.312-0.718) were less likely to initiate ART in time. Conclusion The timely rate of antiviral treatment in Yichang City needs to be further improved. High attention should be paid to cases reported from other places, cases with delayed CD4 cell testing, and cases with high CD4 cell count levels. Treatment mobilization and referral should be done well, and early detection services should be provided in time.
